IL162236A0 - Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use - Google Patents

Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use

Info

Publication number
IL162236A0
IL162236A0 IL16223602A IL16223602A IL162236A0 IL 162236 A0 IL162236 A0 IL 162236A0 IL 16223602 A IL16223602 A IL 16223602A IL 16223602 A IL16223602 A IL 16223602A IL 162236 A0 IL162236 A0 IL 162236A0
Authority
IL
Israel
Prior art keywords
envelopeproteins
dagnostic
virus
therapeutic use
purified hepatitis
Prior art date
Application number
IL16223602A
Other languages
English (en)
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of IL162236A0 publication Critical patent/IL162236A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16223602A 2001-12-18 2002-12-18 Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use IL162236A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2051001A 2001-12-18 2001-12-18
US41835802P 2002-10-16 2002-10-16
PCT/EP2002/014480 WO2003051912A2 (fr) 2001-12-18 2002-12-18 Proteines purifiees du virus de l'hepatite c utilisables en diagnostic et therapie

Publications (1)

Publication Number Publication Date
IL162236A0 true IL162236A0 (en) 2005-11-20

Family

ID=26693530

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16223602A IL162236A0 (en) 2001-12-18 2002-12-18 Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use

Country Status (12)

Country Link
EP (1) EP1461080A2 (fr)
JP (1) JP2005516939A (fr)
KR (1) KR20040076869A (fr)
CN (1) CN1622828A (fr)
AU (1) AU2002361160B2 (fr)
BR (1) BR0215081A (fr)
CA (1) CA2468690A1 (fr)
IL (1) IL162236A0 (fr)
MX (1) MXPA04005891A (fr)
NZ (1) NZ533396A (fr)
RU (1) RU2319505C2 (fr)
WO (1) WO2003051912A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
WO2002085932A2 (fr) 2001-04-24 2002-10-31 Innogenetics N.V. Constructions et methodes relatives a l'expression de proteines d'enveloppe recombinantes du vhc
FR2859221B1 (fr) * 2003-08-28 2005-10-14 Centre Nat Rech Scient Vecteur de co-expression de domaines membranaires de proteines d'enveloppe d'un virus et utilisations
EP1574517A1 (fr) 2004-03-09 2005-09-14 Innogenetics N.V. HCV E1 contenant les ponts disulfure spécifiques
EP1809773B1 (fr) * 2004-10-18 2014-07-16 Globeimmune, Inc. Moyens therapeutiques a base de levure contre l'infection par hepatite c chronique
CN100365124C (zh) * 2005-10-27 2008-01-30 云南大学 一段丙型肝炎病毒特异性cDNA序列的应用
WO2009030872A1 (fr) * 2007-09-07 2009-03-12 Mats Axel Atterdag Persson Matériaux et procédés pour le traitement de l'hépatite c
SI2285408T1 (sl) 2008-06-05 2019-02-28 Ablynx N.V. Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni
NZ597314A (en) 2009-06-05 2013-07-26 Ablynx Nv Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
EP2507262A1 (fr) 2009-11-30 2012-10-10 Ablynx N.V. Séquences d'acides aminés améliorées dirigées contre le virus syncytial respiratoire humain (hrsv) et polypeptides comprenant celles-ci pour la prévention et/ou le traitement d'infections du tractus respiratoire
EP2720716B1 (fr) 2011-06-14 2018-03-21 Globeimmune, Inc. Compositions immunotherapeutiques pour le traitement ou prévention d'une infection par le virus delta de l'hépatite
RU2570553C2 (ru) * 2013-11-20 2015-12-10 Федеральное бюджетное учреждение "Всероссийский научно-исследовательский институт лесоводства и механизации лесного хозяйства (ФБУ ВНИИЛМ) Способ очистки вирусных полиэдров
CN104327170A (zh) * 2014-05-16 2015-02-04 中国疾病预防控制中心病毒病预防控制所 丙型肝炎病毒(hcv)细胞进入抑制肽zte1序列及应用
CN107002079A (zh) 2014-09-17 2017-08-01 衣阿华大学研究基金会 作为免疫调节剂和疫苗组分的病毒rna区段
US20190284230A1 (en) * 2016-09-29 2019-09-19 Macfarlane Burnet Institute For Medical Research And Public Health Limited Assembled glycoproteins
WO2020117760A1 (fr) * 2018-12-03 2020-06-11 Duke University Procédé de purification de nanoparticules et de protéines recombinantes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0992580T3 (da) * 1993-11-04 2005-07-11 Innogenetics Nv Epitoper på human T-celler, som er immundominante for hepatitis C-virus
NZ508797A (en) * 1998-06-24 2004-02-27 Innogenetics N Particles of HCV envelope proteins: use for vaccination

Also Published As

Publication number Publication date
CN1622828A (zh) 2005-06-01
KR20040076869A (ko) 2004-09-03
NZ533396A (en) 2005-04-29
AU2002361160B2 (en) 2008-07-03
EP1461080A2 (fr) 2004-09-29
BR0215081A (pt) 2004-10-19
RU2319505C2 (ru) 2008-03-20
WO2003051912A9 (fr) 2004-07-15
WO2003051912A3 (fr) 2004-03-04
JP2005516939A (ja) 2005-06-09
CA2468690A1 (fr) 2003-06-26
MXPA04005891A (es) 2004-09-13
AU2002361160A1 (en) 2003-06-30
WO2003051912A2 (fr) 2003-06-26
RU2004116914A (ru) 2005-04-20

Similar Documents

Publication Publication Date Title
SI1404347T1 (sl) 4'-substituirani nukleozidi za zdravljenje bolezni posredovanih z virusom hepatitisa c
HUP0400882A3 (en) Oncolytic virus therapy
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
IL165860A0 (en) Administration of therapeutic viruses
EP1364957A4 (fr) Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci
IL152934A0 (en) Methods and compositions for treating hepatitis c virus
EP1569652A4 (fr) Nucleosides n sp 4 /sp -acylcytosines pour le traitement d'infections virales
AU5618501A (en) Dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis
IL157251A0 (en) Hepatitis b virus treatment
AU2003294757A8 (en) Formulations useful against hepatitis c virus infections
IL143798A0 (en) Hepatitis c virus ns3 protease
PL356640A1 (en) Treatment of viral infections using levovirintm
GB0119025D0 (en) Compounds and their therapeutic use
IL151033A0 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
AP2002002432A0 (en) Treatment of viral infections
IL151188A0 (en) Medicament for viral diseases
AU2002332613A1 (en) Compositions and therapeutic methods for viral infection
AU2001234596A1 (en) Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections
AU2002327531A1 (en) Therapeutic compositions and methods for treating viral infection
EP1363611A4 (fr) Therapie de l'hepatite aux retinoides
AU2003299493A8 (en) Compositions and methods for the treatment of hepatitis c virus infection
GB2376943B (en) Compounds and their therapeutic use
GB0112237D0 (en) Compounds and their therapeutic use
SI1436397T1 (sl) Cepivo proti virusu hepatitisa C
GB0122302D0 (en) Preventive and therapeutic antiviral drug for aids hepatitis B Hepatitis C and influenza